DUBLIN--(BUSINESS WIRE)--The "Global Neutropenia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to ...

In an effort to address safety concerns regarding severe neutropenia, the FDA has made changes to requirements for monitoring prescribing, dispensing, and receiving the schizophrenia medicine ...

The American Society of Clinical Oncology (ASCO) has bulked up its advice to clinicians about managing patients who undergo chemotherapy. The organization has issued a new guideline on how and when to ...

Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 -- European Commission ...

X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...

Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer. Curative treatment for patients with ...

The PALLAS trial analyzed the impact of BMI in patients with early hormone receptor positive breast cancer. Body mass index (BMI) had an effect on side effects, dose reductions, early treatment ...

Please provide your email address to receive an email when new articles are posted on . Tbo-filgrastim (Sicor Biotech) is approved for use in adults who malignancies other than blood or bone marrow ...

Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial Furthermore, costs vary with the perspective adopted: providers, payers, patients ...

The Neutropenia Treatment Market was valued at $12,602.5 million in 2019, and is expected to reach $19,303.1 million by 2027, with a CAGR of 5.4% during the forecast period. The Neutropenia Treatment ...